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Purpose/Objective: In vivo dosimetry is an important tool to 
check whether the delivered dose conform to the expected 
dose. For intraoperative radiation therapy (IORT) in partial 
breast irradiation (PBI), this is especially relevant since the 
high dose is delivered in a single fraction. The purpose of this 
study was to compare the given dose to the expected dose 
PBI. 
Materials and Methods: During the period May 2010 - 
October 2014, 292 elderly (60+) patients, diagnosed with 
breast cancer (tumour diameter < 3 cm) were treated with 
IORT in our institution. For 47 of these patients, in vivo 
dosimetry was performed with MOSFETs (metal-oxide 
semiconductor field-effect transistors, TN-502RD) or/and 
GAFCHROMIC EBT2 films. PBI with a total dose of 23.3 Gy at 
100% (21 Gy at 90%) was given during the operation according 
to the method described in the ELIOT study (1). All patients 
were irradiated with electron beams generated with an IORT 
dedicated mobile accelerator (Mobetron, INTRAOP, USA). The 
in vivo dose measurements were done by attaching the first 
MOSFET detector under the bolus at the end of the applicator 
and the second detector attached behind the protection 
plate (6 mm aluminium plus 3 mm copper), which was used 
to shield the thorax. During the dose measurements with 
GAFROMIC films, the first and the second films were placed 
before and behind the protection plate, respectively. 
Calibration of the MOSFET detectors and the GAFCHROMIC 
films was done by measuring the absolute dose with a Roos 
type ionization chamber. The calibration measurements were 
performed with the electron beams of the Mobetron in a 
homemade PMMA phantom at the depth of dose maximum for 
each energy.  
Results: The results of in vivo MOSFET dosimetry for 27 
patients and GAFCHROMIC film dosimetry for 20 patients are 
shown in panels (a) and (b), respectively. The measured with 
MOSFETs entry dose for the breast tissue agrees within 1.7% 
(SD 3.7%) with the expected dose. The dose measured with 
GAFCHROMIC films in breast tissue (before the protection 
plate) was within 3.7% of the prescribed dose. The dose 
measured with the both methods behind the protection plate 
was within 2 Gy.  
 
 
Conclusions: In vivo MOSFET and GAFROMIC film dosimetry 
during IORT was successful for PBI. The results of both 
methods are in a good agreement. The measured entry dose 
for the breast tissue agrees within 1.7% with the expected 
dose. For both methods, the dose to the thoracic wall and 
lungs was lower than 2 Gy even if 12 MeV was applied. 
1. M. Intra, A. Luini, G. Gatti, et al, Surgery (2006) 140:467-
71. 
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Purpose/Objective: To commission a real-time in-vivo 
dosimeter service using a Metal–Oxide–Semiconductor Field-
Effect Transistor (MOSFET) for High Dose Rate (HDR) prostate 
brachytherapy and then apply it to assess ten clinical 
patients.  
Materials and Methods: The MOSFET detector (Best® medical 
Canada) together with the reader (microMOSFET, TN-
502RDM-H) was used at standard bias setting. A Flexitron® 
HDR treatment unit (Elekta AB, Sweden), along with an 
ultrasound (US) based commercial brachytherapy treatment 
planning system Oncentra Prostate, (Elekta AB, Sweden), 
were used.  
Commissioning tests included linearity, calibration, 
reproducibility, anisotropy (azimuthal and polar), 
temperature dependence and energy dependence. Following 
commissioning, MOSFET measurements were performed for 
ten patients in real time under trans-rectal ultrasound image 
guidance, delivering a 15 Gy single fraction to 100% isodose. 
The MOSFET was inserted using an additional needle with the 
clinical dose point position chosen centrally in a low dose 
gradient area. The treatment planning system (TPS) dose was 
exported and the correction factors applied to predict the 
measured voltage of the MOSFET. Correction factors included 
a distance dependent energy correction factor and a 
calibration factor which converted the TPS dose to the 
predicted measured voltage. The best fit used for the 
calibration factor was the power fit which is made up from 
repeated measurements of the calibration factor. 
Results: The MOSFET responds linearly with dose, over the 
clinical dose range (0.01 Gy to 20 Gy), with R2= 0.9991. 
Anisotropy azimuthal and polar resulted in a minimal 
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dependence within the uncertainty of the measurements; 
hence no azimuthal and polar correction factors were applied 
to the measurements. No temperature dependence was 
found within the uncertainty of the measurement. The 
measured patient plans were in good agreement with the 
predicted voltage of the dosimeter with the minimum and 
maximum percentage differences between the measured and 
the predicted of -2.6% and -11.3% respectively. Further 
investigation of the causes of these differences and of per 
needle dose measurements to allow real-time error detection 
is still ongoing. Total uncertainty budget of this study was 
9.97% for k=2. An example of a clinical patient result is given 
in the figure.  
 
 
 
Conclusions: Our study has demonstrated that 
implementation of real-time in-vivo dosimetry for HDR 
prostate brachytherapy using a MOSFET is feasible. Gross 
error detection is possible when the MOSFET is placed in a 
low dose gradient and appropriate correction factors are 
applied.  
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Purpose/Objective: To study if real time in vivo dosimetry, 
performed on the rectal surface with MOSkin detectors 
included on the trans rectal ultrasound (TRUS) probe, may 
evaluate possible discrepancies between calculated and 
delivered doses during US-based HDR prostate brachytherapy. 
Materials and Methods: MOSkins are a specific type of 
MOSFET dosimeter, optimized to measure dose in steep dose 
gradients. Their sensitive volume, defined by the volume of 
the gate oxide, is 4.8 x 10-6 mm3. In this study, two MOSkin 
dosimeters were calibrated and assembled on the surface of 
a TRUS-probe, used for real time on-line treatment planning 
in HDR prostate brachytherapy. During the treatment, the 
TRUS-probe was left inside the rectum and real time 
measures of the delivered dose were performed over 14 
treatment sessions (prescribed dose to the target surface: 
14Gy). 
Measured doses were compared to the doses calculated by 
means of the treatment planning system in the estimated 
detector position both on pre-treatment images (i.e., 
acquired 1-2 hours before treatment and used for treatment 
planning) and on post-treatment images (i.e., acquired 
within 3 minutes after treatment). In the latter case, the 
delivered dose distribution was retrospectively reconstructed 
and assumed as the reference. 
Results: Comparison between planned, reconstructed and in 
vivo measured doses, in terms of average absolute 
differences and maximum discrepancies, are given in the 
following table. 
 
 
Data reported in the table shows that the highest accordance 
resulted between MOSkin readings and doses obtained on 
reconstructed plans, suggesting that in particular cases in 
vivo dosimetry might be a better instrument to estimate the 
dose to the rectum rather than the original treatment 
planning system itself. 
Comparing pre- and post-treatment images, it can be 
demonstrated that the high observed discrepancy between 
treatment and reconstructed plans is mainly due to 
anatomical variations of the prostate shape (i.e., prostate 
swelling with expanding inter-needles distances) and position 
(i.e., shift towards the rectal wall). This discrepancy 
correlated with the treatment planning time. 
Conclusions: Doses delivered to the organs at risk during HDR 
prostate brachytherapy might differ significantly from what is 
calculated in the treatment planning phase, providing the 
need for in vivo dosimetry in this particular radiotherapy 
application. MOSkin dosimeters integrated to the TRUS-probe 
proved to be an accurate instrument to perform real time 
measurement of the dose delivered to the rectal wall. The 
use of the dosimeters was incorporated in our department 
into clinical practice, actions protocol are still under study to 
potentially use the information acquired on-line. 
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